Abstracts of presentations

  1. Reece PA and McKimm-Breschkin J. Zanamivir PK/PD: implications for the treatment of avian influenza (H5N1) infections in humans. Proceedings of EACPT, Edinburgh, July 15, 2009.

  2. Cutler N R; Sramek J J; Seifert R D; Hourani J; Reece P A; Bockbrader H; Sedman A J; Wardle T S.  Maximally tolerated dose of the muscarinic agonist CI-979 in Alzheimer's disease (AD).  Biological Psychiatry 35 (9): 628 (1994).

  3. Cutler N R; Sramek J J; Seifert R D; Hourani J; Reece P A; Bockbrader H; Sedman A J.  Safety and tolerance of the muscarinic agonist CI-979.  Clinical Pharmacology & Therapeutics 55 (2): 174 (1994).

  4. De Vries T M; Siedlik P; Smithers J A; Brown R R; Reece P A; Posvar E L; Sedman A J; Koup J R; Forgue S T.  Effect of multiple-dose tacrine administration on single-dose pharmacokinetics of digoxin, diazepam, and theophylline.  Pharmaceutical Research (New York) 10 (10 SUPPL.): S333 (1993).

  5. De Vries T M; O'Connor-Semmes R L; Guttendorf R J; Reece P A; Posvar E L; Sedman A J; Koup J R; Forgue S T.  Effect of cimetidine and low-dose quinidine on tacrine pharmacokinetics in humans.  Pharmaceutical Research (New york) 10 (10 SUPPLY.): S337 (1993).

  6. Windsor B L; Radulobic L L; Bockbrader H N; Underwood B A; Reece P A; Sedman A J; Chang T.  Application of validated GC-NPD method for quantitation of CI-979 in a clinical interaction study with Maalox TC.  Pharmaceutical Research (New York) 10 (10 SUPPL.): S415 (1993).

  7. Busch J A; Radulovic L L; Reece P A;  Sedman A J; Bockbrader H N.   Effect of food on the bioavailability of Neurontin 400-mg market-image Supro capsules in healthy subjects.  Pharmaceutical Research (New york) 10 (10 SUPPL): S345 (1993).

  8. Reece PA, Dawkins R, Wright S, Rajagopalan R, Sedman AJ.  Dose proportionality and pharmacodynamics of intramuscular CI-977.  Clin Pharmacol Ther 51:189 (1992).

  9. Reece PA, Bockbrader H, Sedman AJ.  Safety, pharmacodynamics, and pharmacokinetics of a new muscarinic agonist, CI-979.  Clin Exp Pharmacol Physiol 21:58 (1992).

  10. Olver IN, Reece PA, Morris RG, Bishop JF, Guentert TW, Hill HS, and Hillcoat BL.  Phase I pharmacokinetic study of doxifluridine given by five-day stepped dose infusion.  Invest New Drugs 7:379 (1989).

  11. Reece PA, Stafford I, Freeman S, Gill PG, Davy M, Abbott RL, Olweny CLM and Denham J.  Creatinine clearance as a predictor of the disposition of the anticancer drug, cisplatin in patients with cancer.  Xth International Congress of Pharmacology, Sydney, August (1987).

  12. Morris RG, Reece PA, Bishop JF and Olver JN.  Relationship between myelosuppression and disposition of the new anticancer drug, trimetrexate.  Xth International Congress of Pharmacology, Sydney, August (1987).

  13. Reece PA, Stafford I, Freeman S, Gill PG, Davy M, Russell J and Khan M. Physiologically based pharmacokinetic modelling of cisplatinum in patients with cancer.  Clin Exp Pharmacol Physiol Suppl 11:45 (1987).

  14. Reece PA et al.  Interpatient differences in the elimination of anti-cancer drugs - a potentially important contributor to differences in response and toxicity.  Medical and Paediatric Oncology 15:134 (1987).

  15. Reece PA, Stafford I, Russell J, Khan M and Gill PG.  Prediction of cisplatinum disposition in patients from creatinine clearance. Relationship between unbound platinum plasma levels and the development of nephrotoxicity.  Medical and Paediatric Oncology 15:122 (1987).

  16. Morris RG, Reece PA, Bishop JF, Olver IN and Raghavan D.  Phase I pharmacokinetic study of the methotrexate analogue, trimetrexate, in patients with advanced cancer.  Medical and Paediatric Oncology 15:124 (1987).

  17. Olver IN, Bishop JF, Raghavan D, Reece PA and Morris RG.  Phase I study of trimetrexate (TMTX) as a five day continuous infusion.  Medical and Paediatric Oncology 15:151 (1987).

  18. Reece PA, Stafford I, Davy M and Freeman S  Disposition of unchanged cisplatin in patients with ovarian cancer.  Proc Amer Assoc Cancer Res 28:193 (1987).

  19. Stafford I, Reece PA, Russell J and Gill PG.  Reduced ability to clear unbound platinum, with repeated courses of cisplatinum to patients.  Clin Exp Pharmacol Physiol Suppl 10:81 (1987).

  20. Morris RG, Reece PA, Dale BM, Kotasek D, Gee D and Sage RE.  Effect of the dietary amino-acid L-leucine on oral melphalan absorption.  Clin Exp Pharmacol Physiol Suppl 10:90 (1987).

  21. Reece PA, Stafford I, Russell J and Gill PG.  Ultrafilterable platinum disposition in patients following cisplatin infusion - What is the correct model?  Abstract 1137, Proc Amer Assoc Cancer Res 27:287 (1986).

  22. Morris RG, Reece PA, Bishop J, Olver J and Raghavan D.  Disposition of a new methotrexate analogue, trimetrexate, given by five day infusion to patients.  Abstract of paper presented at the Third World Conference on Clinical Pharmacology and Therapeutics, Stockholm, Sweden, July 1986.

  23. Powis G, Reece PA, Ingle JN and Ahmann DL.  Cyclophosphamide pharmacokinetics in obese cancer patients.  Acta Pharm Tox 59(Suppl V):296 (1986).

  24. Reece PA, Stafford I, Russell J and Gill PG.  Cisplatinum pharmacokinetics - nonlinear renal clearance and prolonged plasma levels in patients.  Med Pediatr Oncol 13:147 (1985).

  25. Morris RG, Reece PA, Kotasek P, Dale BM and Sage RE.  Food reduces oral melphalan absorption.  Clin Exp Pharmacol Physiol Supp 9:100 (1985).

  26. Reece PA, Stafford I, Russell J and Gill PG.  Nonlinear renal clearance and prolonged plasma levels of unbound platinum in patients administered cisplatinum.  Clin Exp Pharmacol Physiol Supp 9:42 (1985).

  27. Schapel GJ, Robinson MK, Barrell ML, Reece PA, and Texler KC.  Phenytoin (DPH) dosage in severe pre-eclamptic toxaemia (PET).  Clin Exp Pharmacol Physiol Suppl 9:54 55 (1985).

  28. Stafford I, Reece PA, Prager RH, Walker GJ and Zacest R.  The synthesis formulation and clinical pharmacological evaluation of hydrallazine pyruvic acid hydrazone.  Clin Exp Pharmacol Physiol Suppl 9:97 98 (1985).

  29. Reece PA, Stafford I, Russell J and Gill PG.  Cisplatin pretreatment reduces unbound platinum renal clearance in patients.  Abstract 1384, Proc Amer Assoc Cancer Res 26:351 (1985).

  30. Bochner F, Imhoff DM, Reece PA, Dimitriadis E and Ward AD.  Direct measurement of salicyl phenolic glucuronide in human urine.  Abstract of a meeting of the II World Conference on Clinical Pharmacology and Therapeutics, Washington, U.S.A., August 1983.

  31. Reece PA, Cozamanis I and Zacest R  Endralazine - a vasodilator with high systemic bioavailability.  Abstract of a meeting of the II World Conference on Clinical Pharmacology and Therapeutics, Washington, U.S.A., August 1983.

  32. Reece PA and Powis G.  Technique for determining extracellular fluid drug levels - application to cisplatinum pharmacokinetic studies.  Clin Exp Pharmacol Physiol 10(6), (1983).

  33. Reece PA, Cozamanis I and Zacest R.  Simultaneous pharmacokinetic and pharmacodynamic study of endralazine in healthy volunteers. I. Pharmacokinetics Clin Exp Pharmacol Physiol 9:477 (1982).

  34. Zacest R, Cozamanis I and Reece PA.  Simultaneous pharmacokinetic and pharmacodynamic study of endralazine in healthy volunteers.  II. Pharmacodynamics.  Clin Exp Pharmacol Physiol 9:477 478 (1982).

  35. Reece PA, Cozamanis I and Zacest R.  Specific assay and initial pharmacokinetics of a new vasodilator antihypertensive, endralazine. Clin Exper Pharmacol Physiol 8:602 (1981).

  36. Reece PA, Cozamanis I and Zacest R.  HPLC-fluorescence assay for the antihypertensive drug endralazine and two of its metabolites in human plasma.  Abstract of a meeting of the Royal Australian Chemical Institute, Canberra, Australia, August 1981.

  37. Reece PA, Cozamanis I and Zacest R.  New insights into hydralazine plasma clearance following intravenous infusion to human volunteers.  Clin Pharmacol Ther 27:280 (1980).

  38. Cozamanis I, Reece PA and Zacest R.  Fate of oral hydralazine in slow and fast acetylators.  Clin Exper Pharmacol Physiol 7:678-679 (1980).

  39. Reece PA and Zacest R.  Towards specific methods for hydrallazine assay. Clin Exp Pharmacol Physiol 6:207 208 (1979).

  40. Lo M, Reece PA and Riegelman S.  HPLC determination of propranolol and metabolites in plasma and urine.  Clin Exp Pharmacol Physiol 6:698 699 (1979).

  41. Lo M, Reece PA and Riegelman S.  Determination of propranolol and its metabolites in plasma and urine by HPLC.  APha Academy of Pharmaceutical Sciences 25th National Meeting, Abstracts, 8/2, 87 (1978).

  42. Reece PA and Zacest R. Significance of "Apparent Hydrallazine" levels in plasma of man.  Clin Exp Pharmacol Physiol 5:248 (1978).

  43. Zacest R and Reece PA. Hydrallazine metabolism in renal failure.  Aust NZ J Med 7:551 (1977). 
 
 
Preloaded image Preloaded image Preloaded image Preloaded image Preloaded image Preloaded image Preloaded image Preloaded image Preloaded image Preloaded image Preloaded image Preloaded image